GlassScriptPhysician profile
Jacob Sam Koruth
NPI 1265652051
$3,654,413.60
in general payments reported to CMS, 2019-2025
19 companies · $460K in 2025
The $460K reported for 2025 was more than what 99% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60K · 2020: $6,955 · 2021: $153K · 2022: $1.9M · 2023: $538K · 2024: $493K · 2025: $460K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $740K · Consulting Fee: $395K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $218K · Travel and Lodging: $115K · Food and Beverage: $15K · Honoraria: $7,200 · Grant: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $739,992.30 |
| Consulting Fee | $395,434.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $217,864.50 |
| Travel and Lodging | $115,196.00 |
| Food and Beverage | $14,710.67 |
| Honoraria | $7,200.00 |
| Grant | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,582,669.99 | 2021-2025 | Arctic Front Advance, Affera Mapping System, Micra |
| Boston Scientific Corporation | $447,566.79 | 2019-2025 | Farapulse, General - Therapies, Versacross Access Solution |
| Abbott Laboratories | $230,740.63 | 2019-2025 | Ensite, Tacticath Ablation Catheter, Sensor Enabled, Flexability |
| Pulse Biosciences, INC. | $207,189.03 | 2024-2025 | Cellfx, Cellfx |
| Biosense Webster, INC. | $81,604.97 | 2023-2025 | Carto 3, Thermocool Sf |
| Acutus Medical, INC. | $47,494.49 | 2021-2022 | |
| Cardiofocus, INC. | $35,298.53 | 2019-2025 | |
| Abiomed | $10,112.78 | 2021-2024 | Impella |
| Philips North America LLC | $5,400.00 | 2022 | |
| Medical Device Business Services, INC. | $3,366.21 | 2024 | Carto 3 |
| Altathera Pharmaceuticals LLC | $2,000.00 | 2022 | |
| Biotronik INC. | $277.83 | 2019-2024 | Renamic Neo, Amvia Edge |
| Medtronic Vascular, INC. | $199.03 | 2019 | |
| Cardiva Medical, INC. | $146.32 | 2023-2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| E.R. Squibb & Sons, L.L.C. | $134.35 | 2022-2023 | Camzyos |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ebr Systems, INC. | $97.56 | 2025 | |
| Atricure, INC. | $47.04 | 2024-2025 | Epi-Ease Epicardial Access System, Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Janssen Pharmaceuticals, INC | $40.47 | 2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.58 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Koruth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.